|
Real-time Estimate
Cboe BZX
12:00:31 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 93.64 USD | +0.62% |
|
-0.63% | +17.84% |
| 08-25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology | MT |
| 08-25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology, CNBC Reports | MT |
| Market Cap | 119B 103B 96.16B 87.78B 165B 11,375B 166B 1,141B 445B 5,742B 447B 437B 19,040B | P/E 2026 * |
13.7x | P/E 2027 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise Value | 171B 147B 138B 126B 237B 16,337B 238B 1,639B 639B 8,247B 642B 628B 27,345B | EV / Sales 2026 * |
0.41x | EV / Sales 2027 * | 0.39x |
| Free-Float |
71.17% | Yield 2026 * |
2.86% | Yield 2027 * | 2.94% |
Last Transcript : CVS Health Corporation
| 1 day | +0.05% | ||
| 1 week | -0.90% | ||
| Current month | -10.69% | ||
| 1 month | -10.69% | ||
| 3 months | +2.92% | ||
| 6 months | +15.87% | ||
| Current year | +17.52% |
| 1 week | 92.71 |  | 94.86 |
| 1 month | 92.35 | | 105.69 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 5/31/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 5/21/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.02% | -0.90% | +25.88% | +43.11% | 119B | |
| +0.03% | -2.75% | +2.78% | +50.53% | 90.46B | |
| -0.90% | -1.60% | -1.20% | +56.24% | 29.97B | |
| -0.46% | -1.42% | +34.53% | +82.82% | 26.79B | |
| -2.14% | -2.14% | -3.40% | -4.16% | 22.19B | |
| -0.61% | -4.76% | +43.15% | +242.08% | 21.48B | |
| -0.11% | +2.72% | -9.33% | +23.73% | 14.84B | |
| -1.03% | -2.33% | -10.63% | -11.65% | 12.28B | |
| -0.81% | +1.71% | +31.08% | +75.27% | 11.52B | |
| +0.59% | +3.13% | -13.62% | +72.49% | 10.32B | |
| Average | -0.51% | -0.03% | +9.92% | +63.05% | 35.89B | |
| Weighted average by Cap. | -0.30% | -0.75% | +13.99% | +57.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 360B 337B 308B 580B 39,924B 582B 4,004B 1,562B 20,153B 1,568B 1,534B 66,826B | 430B 370B 347B 317B 597B 41,051B 599B 4,117B 1,606B 20,722B 1,613B 1,578B 68,712B |
| Net income | 8.79B 7.58B 7.1B 6.49B 12.22B 840B 12.26B 84.29B 32.89B 424B 33.01B 32.3B 1,407B | 9.11B 7.85B 7.36B 6.72B 12.66B 871B 12.7B 87.32B 34.07B 439B 34.2B 33.46B 1,457B |
| Net Debt | 51.92B 44.74B 41.94B 38.29B 72.13B 4,962B 72.36B 498B 194B 2,505B 195B 191B 8,305B | 49.15B 42.35B 39.71B 36.25B 68.28B 4,697B 68.5B 471B 184B 2,371B 185B 181B 7,862B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-31 | US$93.56 | +0.53% | 976,125 |
| 26-08-28 | US$93.06 | +0.15% | 3,994,223 |
| 26-08-27 | US$92.92 | -1.48% | 4,330,313 |
| 26-08-26 | US$94.32 | +1.53% | 6,162,107 |
| 26-08-25 | US$92.90 | -1.29% | 4,102,481 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
